JKB-122

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameJKB-122
Drug Alias NameJKB-122
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulatorsToll like receptor 4 agonists
TargetsToll like receptor 4
Therapy Area/IndicationsImmune System DiseasesHepatitis, AutoimmuneMetabolic Dysfunction-Associated Steatotic Liver Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesTaiwanj Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiostax CorpTaiwanj Pharmaceuticals Co LtdStandard Chem & Pharm Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsImmune System DiseasesHepatitis, AutoimmuneMetabolic Dysfunction-Associated Steatotic Liver Disease +[5] 
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A